| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 1,249,026 | 773,689 | 594,189 | 500,919 |
| Cost of goods sold | 197,231 | 142,029 | 70,183 | 81,980 |
| Cost of collaborations and royalties | 2,923 | 924 | 858 | 3,925 |
| Research and development | 358,814 | 323,621 | 265,122 | 270,926 |
| Selling, general and administrative | 322,076 | 323,314 | 239,949 | 220,993 |
| Total operating costs and expenses | 881,044 | 789,888 | 576,112 | 577,824 |
| Income (loss) from operations | 367,982 | -16,199 | 18,077 | -76,905 |
| Interest expense | 44,398 | 40,246 | 38,646 | 34,376 |
| Interest income | 28,681 | 27,486 | 28,673 | 32,146 |
| Loss related to convertible debt | 39,146 | - | - | - |
| Other expense, net | -74,150 | -6,399 | -49,700 | -29,528 |
| Total other expense, net | -129,013 | -19,159 | -59,673 | -31,758 |
| Income (loss) before income taxes | 238,969 | -35,358 | -41,596 | -108,663 |
| Benefit from (provision for) income taxes | -12,115 | 30,919 | 15,883 | 2,907 |
| Net income (loss) | 251,084 | -66,277 | -57,479 | -111,570 |
| Unrealized gains on marketable securities | 1,131 | -343 | 1,030 | 9,078 |
| Defined benefit pension plans, net of tax | - | - | -55 | -30 |
| Foreign currency translation gains (losses) | 6,993 | 7,855 | - | - |
| Foreign currency translation loss | - | - | -4,084 | 703 |
| Defined benefit pension plans, net of tax | -53 | -53 | - | - |
| Total other comprehensive loss | - | - | -2,999 | 9,811 |
| Net other comprehensive income (loss) | 8,177 | 7,565 | - | - |
| Comprehensive income (loss) | 259,261 | -58,712 | -60,478 | -101,759 |
| Net income (loss) per common sharebasic (in dollars per share) | 1.91 | -0.51 | -0.44 | -0.87 |
| Net income (loss) per common sharediluted (in dollars per share) | 1.84 | -0.51 | -0.44 | -0.87 |
| Weighted-average common shares - basic (in shares) | 131,447,000 | 130,628,000 | 129,676,000 | 128,590,000 |
| Weighted-average common shares - diluted (in shares) | 137,348,000 | 130,628,000 | 129,676,000 | 128,590,000 |
ALNYLAM PHARMACEUTICALS, INC. (ALNY)
ALNYLAM PHARMACEUTICALS, INC. (ALNY)